NDA 020387 · Organon
Hyzaar
Hydrochlorothiazide, Losartan Potassium · Oral · Thiazide Diuretic
Last checked: Nov 19, 2026Latest source record: Jun 20, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Apr 28, 1995
Approved uses
4
Original approval plus efficacy supplements
Registered trials
450
138 Phase 3, 14 recruiting
FAERS reports
11,595
7,498 serious, 698 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue HYZAAR as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) ] . WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue HYZAAR as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )
What it is approved for
From the label in effect Nov 26, 2025.
HYZAAR is a combination of losartan, an angiotensin II receptor blocker (ARB) and hydrochlorothiazide, a diuretic indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) 1.1 Hypertension HYZAAR ® is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is...
Mechanism: Losartan Potassium Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)], is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor found in many tissues (e.g., vascular...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 20, 2005 Supplement 37 · Efficacy ReviewLabelLetter
- Apr 5, 2005 Supplement 33 · Efficacy LabelLetter
- Sep 30, 2003 Supplement 27 · Efficacy LabelReviewLetter
- Apr 28, 1995 Original approval · Type 4 - New Combination
3 products under this application
- HYZAAR · HYDROCHLOROTHIAZIDE 25MG; LOSARTAN POTASSIUM 100MG · TABLET, ORAL · Prescription · TE AB
- HYZAAR · HYDROCHLOROTHIAZIDE 12.5MG; LOSARTAN POTASSIUM 100MG · TABLET, ORAL · Prescription · TE AB
- HYZAAR · HYDROCHLOROTHIAZIDE 12.5MG; LOSARTAN POTASSIUM 50MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Hydrochlorothiazide" as an intervention, any sponsor and status, largest first.
- INVEST: INternational VErapamil SR Trandolapril STudyPivotal-lookingCompleted
University of FloridaAcademic, hospital or other
NCT00133692 · 22,000 participants · Start Sep 1997
Drug: Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ); Atenolol/HCTZ/Trandolapril · For: Hypertension; Coronary Artery Disease
Sites: Gainesville, Florida
- Diuretic Comparison ProjectPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT02185417 · 20,723 participants · Start Jun 15, 2016 · Primary completion Oct 15, 2022
Drug: Hydrochlorothiazide (HCTZ); Chlorthalidone (CTD) · For: Hypertension
Sites: Birmingham, Alabama; Anchorage, Alaska; Fayetteville, Arkansas · 70 sites in all
- Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential HypertensionPivotal-lookingCompleted
Oslo University HospitalAcademic, hospital or other
NCT06395194 · 15,313 participants · Start Sep 27, 1997 · Primary completion Sep 5, 2003
Drug: Cardiac outcomes on treatment with valsartan; Cardiac outcomes on treatment with amlodipine · For: Essential Hypertension
Centro Neurológico de Pesquisa e Reabiitação, BrazilAcademic, hospital or other
NCT03147092 · 15,000 participants (planned) · Start Feb 1, 2018 · Primary completion Jun 30, 2020
Drug: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,; Atenolol and 2 more · For: Hypertension; Blood Pressure
- Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic HypertensionPivotal-lookingTerminated
NovartisNovartis (NVS)
NCT00170950 · 11,506 participants · Start Oct 2003 · Primary completion Jan 2008
Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1; Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2 and 4 more · For: Hypertension
Sites: East Hanover, New Jersey; Denmark, Denmark; Finland, Finland · 5 sites in all
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPillPivotal-lookingCompleted
Tehran University of Medical SciencesAcademic, hospital or other
NCT01271985 · 8,410 participants · Start Feb 2011 · Primary completion Jan 2019
Drug: PolyPill · For: Cardiovascular Diseases
Sites: Gonbad, Iran
- Strategy of Blood Pressure Intervention in the Elderly Hypertensive PatientsPivotal-lookingStatus unknown
Chinese Academy of Medical Sciences, Fuwai HospitalAcademic, hospital or other
NCT03015311 · 8,000 participants (planned) · Start Jan 15, 2017 · Primary completion Dec 31, 2020
Drug: Intensive BP control; Standard BP control · For: Primary Hypertension
Sites: Beijing, China; Lanzhou, China; Guangzhou, China · 42 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea773
- drug ineffective742
- fatigue692
- dizziness594
- headache563
- diarrhoea536
- pain515
- dyspnoea513
- arthralgia453
- asthenia451
- vomiting407
- hypertension380
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 470 |
| 2005 | 589 |
| 2006 | 625 |
| 2007 | 621 |
| 2008 | 610 |
| 2009 | 677 |
| 2010 | 843 |
| 2011 | 766 |
| 2012 | 760 |
| 2013 | 445 |
| 2014 | 616 |
| 2015 | 652 |
| 2016 | 722 |
| 2017 | 493 |
| 2018 | 506 |
| 2019 | 568 |
| 2020 | 381 |
| 2021 | 233 |
| 2022 | 275 |
| 2023 | 190 |
| 2024 | 179 |
| 2025 | 229 |
| 2026 | 144 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Hyzaar (Losartan/Hydrochlorothiazide)
2024 spending
$1.4M
Beneficiaries
883
3,947 claims
Per beneficiary
$1,626
$5.50 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $493,683 |
| 2022 | $1,861,338 |
| 2023 | $1,745,229 |
| 2024 | $1,435,374 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events.
Ishani A, Cushman WC, Leatherman SM, et al. · N Engl J Med 2022 · Comparative Study, Pragmatic Clinical Trial
- Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence.
Dhayat NA, Bonny O, Roth B, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects.
Roush GC, Ernst ME, Kostis JB, et al. · Hypertension 2015 · Meta-Analysis, Systematic Review
- Oslo Hypertension Study.
Leren P, Helgeland A · Drugs 1986 · Clinical Trial, Randomized Controlled Trial
- Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
Jamerson K, Weber MA, Bakris GL, et al. · N Engl J Med 2008 · Comparative Study, Multicenter Study
- Chlorthalidone vs Hydrochlorothiazide and Kidney Outcomes in Patients With Hypertension: A Secondary Analysis of a Randomized Clinical Trial.
Ishani A, Hau C, Raju S, et al. · JAMA Netw Open 2024 · Randomized Controlled Trial, Comparative Study
Sponsor: Organon
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.